T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Abstract Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress. Methods T2 Protect AD (T2), a phase 2 randomized placebo‐controlled trial o...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
المؤلفون الرئيسيون:	Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2022-01-01
الموضوعات:	Alzheimer's disease clinical trial drug development pharmacologic recruitment
الوصول للمادة أونلاين:	https://doi.org/10.1002/trc2.12265